Medivir AB Release: New Phase 3 Data From Once-Daily Simeprevir Presented At The Conference Of The Asian Pacific Association For The Study Of The Liver (APASL)
Stockholm, Sweden — Medivir AB (OMX: MVIR) today announced that new phase III data for the once-daily protease inhibitor simeprevir have been presented at the Conference of the Asian Pacific Association for the Study of the Liver (APASL) in Brisbane, Australia.
Help employers find you! Check out all the jobs and post your resume.